2311 GMT - Morgans senses a buying opportunity in skin-healing tech developer PolyNovo. The stock has fallen roughly 25% since the end of September, which analyst Scott Power thinks is partly because PolyNovo didn't give a trading update at its annual meeting of shareholders. "Consensus has revenue growth of 29% for FY 2025 which will be skewed to the 2H and we are confident it can be achieved," Morgans says. "Growth of 20%+ is expected to continue in FY26/27 driven by regional expansion as well as additional indications." Morgans has a A$2.85/share price target and add call on PolyNovo, which ended Monday at A$2.04. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
November 25, 2024 18:11 ET (23:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。